# Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

> **NCT05823402** · NA · UNKNOWN · sponsor: **BAMF Health** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** SPECT/CT

## Key facts

- **NCT ID:** NCT05823402
- **Lead sponsor:** BAMF Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05823402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05823402, "Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05823402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*